Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: Findings from the global registry of acute coronary events (GRACE)
Identifieur interne : 00BC27 ( Main/Merge ); précédent : 00BC26; suivant : 00BC28Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: Findings from the global registry of acute coronary events (GRACE)
Auteurs : Gilles Montalescot [France] ; Frans Van De Werf [Belgique] ; Dietrich C. Gulba [Allemagne] ; Álvaro Avezum [Brésil] ; David Brieger [Australie] ; Brian M. Kennelly [États-Unis] ; Tomasz Mazurek [Pologne] ; Frederick Spencer [États-Unis] ; Kami White [États-Unis] ; Joel M. Gore [États-Unis]Source :
- Catheterization and Cardiovascular Interventions [ 1522-1946 ] ; 2003-11.
English descriptors
- KwdEn :
- Abciximab, Acute phase, Acute reperfusion, Angioplasty, Bailout prescriptions, Balloon angioplasty, Baseline, Baseline characteristics, Biochemical marker, Bundle branch block, Cabg, Cardiac, Cardiac arrest, Cardiac marker enzyme, Cardiogenic shock, Cardiology department, Coll cardiol, Concomitant diseases, Coronary care unit, Coronary disease, Coronary stenting, Days death, Engl, Global registry, Glycoprotein, Glycoprotein inhibitors, Glycoprotein receptor blockade, Hazard ratio, Hemodynamic instability, Higher mortality rate, Higher rates, Immediate angioplasty, Infarct artery stenting, Infarction, Inhibitor, Intravenous, Median years, Medical history, Medication, Multinational registry, Myocardial, Myocardial infarction, Patient groups, Platelet glycoprotein blockade, Present study, Previous cabg, Previous medications, Primary angioplasty, Randomized, Randomized trial, Randomized trials, Real world, Reference group, Registry data, Renal failure, Reperfusion, Segment elevation, Stent, Stent implantation, Stenting, Survival rate, Thrombolytic, Thrombolytic therapy, Transient ischemic attack, Unselected patients, Unstable angina, Ventricular function.
- Teeft :
- Abciximab, Acute phase, Acute reperfusion, Angioplasty, Bailout prescriptions, Balloon angioplasty, Baseline, Baseline characteristics, Biochemical marker, Bundle branch block, Cabg, Cardiac, Cardiac arrest, Cardiac marker enzyme, Cardiogenic shock, Cardiology department, Coll cardiol, Concomitant diseases, Coronary care unit, Coronary disease, Coronary stenting, Days death, Engl, Global registry, Glycoprotein, Glycoprotein inhibitors, Glycoprotein receptor blockade, Hazard ratio, Hemodynamic instability, Higher mortality rate, Higher rates, Immediate angioplasty, Infarct artery stenting, Infarction, Inhibitor, Intravenous, Median years, Medical history, Medication, Multinational registry, Myocardial, Myocardial infarction, Patient groups, Platelet glycoprotein blockade, Present study, Previous cabg, Previous medications, Primary angioplasty, Randomized, Randomized trial, Randomized trials, Real world, Reference group, Registry data, Renal failure, Reperfusion, Segment elevation, Stent, Stent implantation, Stenting, Survival rate, Thrombolytic, Thrombolytic therapy, Transient ischemic attack, Unselected patients, Unstable angina, Ventricular function.
Abstract
Stenting and GP IIb/IIIa inhibition are promising adjunctive therapies in PCI. The Global Registry of Acute Coronary Events (GRACE) is a registry of unselected patients with acute coronary syndromes, allowing for the study of treatments in a real‐world environment. Data from GRACE patients with AMI who underwent PCI were analyzed. After adjusting for demographics, baseline characteristics, and previous medications, treatment with GP IIb/IIIa inhibitors and a stent and treatment with a stent alone were significant predictors of survival at 6 months. Stents were used in 90.9% of patients. GP IIb/IIIa inhibitors were used in 59.7%; in most cases they were started after the beginning of the procedure. The in‐hospital death rate (7.6%) was highest in patients undergoing urgent PCI. Mortality at 6 months following PCI was 14.4% among patients who received neither GP IIb/IIIa inhibitors nor a stent, compared to patients who received both GP IIb/IIIa inhibitors and a stent (7.3%), GP IIb/IIIa inhibitors alone (12.8%), or a stent alone (6.7%) Catheter Cardiovasc Interv 2003;60:360–367. © 2003 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/ccd.10653
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000E98
- to stream Istex, to step Curation: 000E98
- to stream Istex, to step Checkpoint: 001A94
Links to Exploration step
ISTEX:4F18BDDA2A4C275BBA87B8D14097CF9269D722A4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: Findings from the global registry of acute coronary events (GRACE)</title><author><name sortKey="Montalescot, Gilles" sort="Montalescot, Gilles" uniqKey="Montalescot G" first="Gilles" last="Montalescot">Gilles Montalescot</name></author><author><name sortKey="Van De Werf, Frans" sort="Van De Werf, Frans" uniqKey="Van De Werf F" first="Frans" last="Van De Werf">Frans Van De Werf</name></author><author><name sortKey="Gulba, Dietrich C" sort="Gulba, Dietrich C" uniqKey="Gulba D" first="Dietrich C." last="Gulba">Dietrich C. Gulba</name></author><author><name sortKey="Avezum, Alvaro" sort="Avezum, Alvaro" uniqKey="Avezum A" first="Álvaro" last="Avezum">Álvaro Avezum</name></author><author><name sortKey="Brieger, David" sort="Brieger, David" uniqKey="Brieger D" first="David" last="Brieger">David Brieger</name></author><author><name sortKey="Kennelly, Brian M" sort="Kennelly, Brian M" uniqKey="Kennelly B" first="Brian M." last="Kennelly">Brian M. Kennelly</name></author><author><name sortKey="Mazurek, Tomasz" sort="Mazurek, Tomasz" uniqKey="Mazurek T" first="Tomasz" last="Mazurek">Tomasz Mazurek</name></author><author><name sortKey="Spencer, Frederick" sort="Spencer, Frederick" uniqKey="Spencer F" first="Frederick" last="Spencer">Frederick Spencer</name></author><author><name sortKey="White, Kami" sort="White, Kami" uniqKey="White K" first="Kami" last="White">Kami White</name></author><author><name sortKey="Gore, Joel M" sort="Gore, Joel M" uniqKey="Gore J" first="Joel M." last="Gore">Joel M. Gore</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4F18BDDA2A4C275BBA87B8D14097CF9269D722A4</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1002/ccd.10653</idno><idno type="url">https://api.istex.fr/document/4F18BDDA2A4C275BBA87B8D14097CF9269D722A4/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000E98</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000E98</idno><idno type="wicri:Area/Istex/Curation">000E98</idno><idno type="wicri:Area/Istex/Checkpoint">001A94</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001A94</idno><idno type="wicri:doubleKey">1522-1946:2003:Montalescot G:stenting:and:glycoprotein</idno><idno type="wicri:Area/Main/Merge">00BC27</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: Findings from the global registry of acute coronary events (GRACE)</title><author><name sortKey="Montalescot, Gilles" sort="Montalescot, Gilles" uniqKey="Montalescot G" first="Gilles" last="Montalescot">Gilles Montalescot</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Service de Cardiologie, Pitié‐Salpêtrière Hospital, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">France</country></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Correspondence address: Institut de Cardiologie, Bureau 2‐236, Centre Hospitalier Universitaire Pitié‐Salpêtrière, 47 Blvd de l'Hôpital, 75013, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement><region type="région" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Van De Werf, Frans" sort="Van De Werf, Frans" uniqKey="Van De Werf F" first="Frans" last="Van De Werf">Frans Van De Werf</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>Cardiology U.Z. Gasthuisberg, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Gulba, Dietrich C" sort="Gulba, Dietrich C" uniqKey="Gulba D" first="Dietrich C." last="Gulba">Dietrich C. Gulba</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Cardiology Department, Krankenhaus Düren Medizinische Klinik, Düren</wicri:regionArea><wicri:noRegion>Düren</wicri:noRegion><wicri:noRegion>Düren</wicri:noRegion></affiliation></author><author><name sortKey="Avezum, Alvaro" sort="Avezum, Alvaro" uniqKey="Avezum A" first="Álvaro" last="Avezum">Álvaro Avezum</name><affiliation wicri:level="3"><country xml:lang="fr">Brésil</country><wicri:regionArea>Coronary Care Unit, CTI‐A Hospital Albert Einstein, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Brieger, David" sort="Brieger, David" uniqKey="Brieger D" first="David" last="Brieger">David Brieger</name><affiliation wicri:level="3"><country xml:lang="fr">Australie</country><wicri:regionArea>Coronary Care Unit, Concord Hospital, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Kennelly, Brian M" sort="Kennelly, Brian M" uniqKey="Kennelly B" first="Brian M." last="Kennelly">Brian M. Kennelly</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Cardiology Department, Hoag Memorial Hospital Presbyterian, Newport Beach</wicri:cityArea></affiliation></author><author><name sortKey="Mazurek, Tomasz" sort="Mazurek, Tomasz" uniqKey="Mazurek T" first="Tomasz" last="Mazurek">Tomasz Mazurek</name><affiliation wicri:level="1"><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Cardiology, Grochowski Hospital, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Spencer, Frederick" sort="Spencer, Frederick" uniqKey="Spencer F" first="Frederick" last="Spencer">Frederick Spencer</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Center for Outcomes Research, University of Massachusetts Medical School, Worcester</wicri:cityArea></affiliation></author><author><name sortKey="White, Kami" sort="White, Kami" uniqKey="White K" first="Kami" last="White">Kami White</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Center for Outcomes Research, University of Massachusetts Medical School, Worcester</wicri:cityArea></affiliation></author><author><name sortKey="Gore, Joel M" sort="Gore, Joel M" uniqKey="Gore J" first="Joel M." last="Gore">Joel M. Gore</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Catheterization and Cardiovascular Interventions</title><title level="j" type="alt">CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS</title><idno type="ISSN">1522-1946</idno><idno type="eISSN">1522-726X</idno><imprint><biblScope unit="vol">60</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="360">360</biblScope><biblScope unit="page" to="367">367</biblScope><biblScope unit="page-count">8</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2003-11">2003-11</date></imprint><idno type="ISSN">1522-1946</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1522-1946</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abciximab</term><term>Acute phase</term><term>Acute reperfusion</term><term>Angioplasty</term><term>Bailout prescriptions</term><term>Balloon angioplasty</term><term>Baseline</term><term>Baseline characteristics</term><term>Biochemical marker</term><term>Bundle branch block</term><term>Cabg</term><term>Cardiac</term><term>Cardiac arrest</term><term>Cardiac marker enzyme</term><term>Cardiogenic shock</term><term>Cardiology department</term><term>Coll cardiol</term><term>Concomitant diseases</term><term>Coronary care unit</term><term>Coronary disease</term><term>Coronary stenting</term><term>Days death</term><term>Engl</term><term>Global registry</term><term>Glycoprotein</term><term>Glycoprotein inhibitors</term><term>Glycoprotein receptor blockade</term><term>Hazard ratio</term><term>Hemodynamic instability</term><term>Higher mortality rate</term><term>Higher rates</term><term>Immediate angioplasty</term><term>Infarct artery stenting</term><term>Infarction</term><term>Inhibitor</term><term>Intravenous</term><term>Median years</term><term>Medical history</term><term>Medication</term><term>Multinational registry</term><term>Myocardial</term><term>Myocardial infarction</term><term>Patient groups</term><term>Platelet glycoprotein blockade</term><term>Present study</term><term>Previous cabg</term><term>Previous medications</term><term>Primary angioplasty</term><term>Randomized</term><term>Randomized trial</term><term>Randomized trials</term><term>Real world</term><term>Reference group</term><term>Registry data</term><term>Renal failure</term><term>Reperfusion</term><term>Segment elevation</term><term>Stent</term><term>Stent implantation</term><term>Stenting</term><term>Survival rate</term><term>Thrombolytic</term><term>Thrombolytic therapy</term><term>Transient ischemic attack</term><term>Unselected patients</term><term>Unstable angina</term><term>Ventricular function</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Abciximab</term><term>Acute phase</term><term>Acute reperfusion</term><term>Angioplasty</term><term>Bailout prescriptions</term><term>Balloon angioplasty</term><term>Baseline</term><term>Baseline characteristics</term><term>Biochemical marker</term><term>Bundle branch block</term><term>Cabg</term><term>Cardiac</term><term>Cardiac arrest</term><term>Cardiac marker enzyme</term><term>Cardiogenic shock</term><term>Cardiology department</term><term>Coll cardiol</term><term>Concomitant diseases</term><term>Coronary care unit</term><term>Coronary disease</term><term>Coronary stenting</term><term>Days death</term><term>Engl</term><term>Global registry</term><term>Glycoprotein</term><term>Glycoprotein inhibitors</term><term>Glycoprotein receptor blockade</term><term>Hazard ratio</term><term>Hemodynamic instability</term><term>Higher mortality rate</term><term>Higher rates</term><term>Immediate angioplasty</term><term>Infarct artery stenting</term><term>Infarction</term><term>Inhibitor</term><term>Intravenous</term><term>Median years</term><term>Medical history</term><term>Medication</term><term>Multinational registry</term><term>Myocardial</term><term>Myocardial infarction</term><term>Patient groups</term><term>Platelet glycoprotein blockade</term><term>Present study</term><term>Previous cabg</term><term>Previous medications</term><term>Primary angioplasty</term><term>Randomized</term><term>Randomized trial</term><term>Randomized trials</term><term>Real world</term><term>Reference group</term><term>Registry data</term><term>Renal failure</term><term>Reperfusion</term><term>Segment elevation</term><term>Stent</term><term>Stent implantation</term><term>Stenting</term><term>Survival rate</term><term>Thrombolytic</term><term>Thrombolytic therapy</term><term>Transient ischemic attack</term><term>Unselected patients</term><term>Unstable angina</term><term>Ventricular function</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Stenting and GP IIb/IIIa inhibition are promising adjunctive therapies in PCI. The Global Registry of Acute Coronary Events (GRACE) is a registry of unselected patients with acute coronary syndromes, allowing for the study of treatments in a real‐world environment. Data from GRACE patients with AMI who underwent PCI were analyzed. After adjusting for demographics, baseline characteristics, and previous medications, treatment with GP IIb/IIIa inhibitors and a stent and treatment with a stent alone were significant predictors of survival at 6 months. Stents were used in 90.9% of patients. GP IIb/IIIa inhibitors were used in 59.7%; in most cases they were started after the beginning of the procedure. The in‐hospital death rate (7.6%) was highest in patients undergoing urgent PCI. Mortality at 6 months following PCI was 14.4% among patients who received neither GP IIb/IIIa inhibitors nor a stent, compared to patients who received both GP IIb/IIIa inhibitors and a stent (7.3%), GP IIb/IIIa inhibitors alone (12.8%), or a stent alone (6.7%) Catheter Cardiovasc Interv 2003;60:360–367. © 2003 Wiley‐Liss, Inc.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00BC27 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 00BC27 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:4F18BDDA2A4C275BBA87B8D14097CF9269D722A4
|texte= Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: Findings from the global registry of acute coronary events (GRACE)
}}
| This area was generated with Dilib version V0.6.33. |  |